| Code | CSB-RA980158MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to BD311, targeting vascular endothelial growth factor (VEGF), a critical signaling protein that regulates angiogenesis and vascular permeability. VEGF plays a pivotal role in both physiological and pathological blood vessel formation by binding to VEGF receptors on endothelial cells, initiating cascades that promote cell proliferation, migration, and survival. Dysregulated VEGF signaling is implicated in numerous diseases, including cancer progression and metastasis, diabetic retinopathy, age-related macular degeneration, and inflammatory disorders where aberrant neovascularization contributes to pathology.
BD311 is an established research reagent used extensively in studies investigating VEGF-mediated angiogenesis and its therapeutic inhibition. This biosimilar antibody provides researchers with a reliable tool for examining VEGF expression, localization, and functional activity in various experimental systems. It supports investigations into tumor angiogenesis, vascular biology, and mechanisms underlying VEGF-driven diseases, facilitating the development of anti-angiogenic strategies and enhancing our understanding of vascular homeostasis in health and disease.
There are currently no reviews for this product.